Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus.
Open accessThe DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.
Abstract
The cytosine analogue decitabine alters hematopoietic differentiation. For example, decitabine treatment increases self-renewal of normal hematopoietic stem cells. The mechanisms underlying decitabine-induced shifts in differentiation are poorly understood, but likely relate to the ability of decitabine to deplete the chromatin-modifying enzyme DNA methyltransferase 1 (DNMT1), which plays a central role in transcription repression. HOXB4 is a transcription factor that promotes hematopoietic stem cell self-renewal. In hematopoietic precursors induced to differentiate by the lineage-specifying transcription factor Pu.1 or by the cytokine granulocyte-colony stimulating factor, there is rapid repression of HOXB4 and other stem cell genes. Depletion of DNMT1 using shRNA or decitabine prevents HOXB4 repression by Pu.1 or granulocyte-colony stimulating factor and maintains hematopoietic precursor self-renewal. In contrast, depletion of DNMT1 by decitabine 6 hours after the differentiation stimulus, that is, after repression of HOXB4 has occurred, augments differentiation. Therefore, DNMT1 is required for the early repression of stem cell genes, which occurs in response to a differentiation stimulus, providing a mechanistic explanation for the observation that decitabine can maintain or increase hematopoietic stem cell self-renewal in the presence of a differentiation stimulus. Using decitabine to deplete DNMT1 after this early repression phase does not impair progressive differentiation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, in normal HSC which do not express high levels of lineage-specifying TF, DNMT1 depletion prevents stem cell gene repression by differentiation stimuli, thereby maintaining stem cell phenotype (6–15).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrast, treatment of normal hematopoietic stem cells with HDAC inhibitors has the opposite effect, maintaining self-renewal,44,48–50 possibly by preventing repression of stem cell genes by differentiation stimuli.44”
From RUNX1 regulates corepressor interactions of PU.1 (2011) · cites this paper as [44]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Hematopoietic precursors subject to a cytokine differentiation stimulus rapidly repress key stem cell genes.44”
From RUNX1 regulates corepressor interactions of PU.1 (2011) · cites this paper as [44]
In the citing paper
“The DNA hypomethylating drug decitabine maintains normal hematopoietic stem cell (HSC) self-renewal but induces terminal differentiation in acute myeloid leukemia (AML) cells.”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ghoshal, K., Datta, J., Majumder, S., Bai, S., Kutay, H., Motiwala, T., & Jacob, S. T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.11.4727-4741.2005 · Cited by 431 · cited 3×
“We have shown that the concentrations of decitabine used here deplete DNMT1 without causing measurable DNA damage or apoptosis in normal human hematopoietic precursors.4 Others have shown that decitabine depletes the maintenance DNA methyltransferase DNMT1 (11), but not the de novo DNA methyltransferases DNMT3A and DN…”
BackgroundRetractedCellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831
The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation
Wang, J., Hevi, S., Kurash, J. K., Lei, H., Gay, F., Bajko, J., Su, H., Sun, W., Chang, H., Xu, G., et al. (2009) · Nature Genetics · doi:10.1038/ng.268 · Cited by 815 · cited 1×
“13) and histone demethylase protein complexes that remove methylation marks of transcription activation (14).”
BackgroundSauvageau, G., Thorsteinsdottir, U., Eaves, C. J., Lawrence, H. J., Largman, C., Lansdorp, P. M., & Humphries, R. K. (1995) · Genes & Development · doi:10.1101/gad.9.14.1753 · Cited by 587 · cited 1×
“1-induced HoxB4 repression and differentiation Hematopoietic cell fate is driven by key transcription factors such as HOXB4, which promotes hematopoietic stem cell self-renewal (22), and the lineage-specifying factor PU.”
BackgroundCreusot, F., Acs, G., & Christman, J. K. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68144-5 · Cited by 564
DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction
Bröske, A.-M., Vockentanz, L., Kharazi, S., Huska, M. R., Mancini, E., Scheller, M., Kuhl, C., Enns, A., Prinz, M., Jaenisch, R., et al. (2009) · Nature Genetics · doi:10.1038/ng.463 · Cited by 478 · cited 2×
“Mol Cancer Ther; 9(6) June 2010 using a hypomorphic Dnmt1 allele (31).”
BackgroundMyeloid Lineage Commitment from the Hematopoietic Stem Cell
Iwasaki, H., & Akashi, K. (2007) · Immunity · doi:10.1016/j.immuni.2007.06.004 · Cited by 394
Trowbridge, J. J., Snow, J. W., Kim, J., & Orkin, S. H. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.08.016 · Cited by 373 · cited 1×
“In a murine model of inducible knockout of Dnmt1 in adult mice, defects in the hematopoietic stem cell compartment and in progenitors suggested that Dnmt1 is required for hematopoietic stem cell self-renewal and differentiation (30).”
BackgroundDifferentiation therapy of leukemia: 3 decades of development.
Nowak, D., Stewart, D., & Koeffler, H. P. (2009) · Blood · doi:10.1182/blood-2009-01-198911 · Cited by 348 · cited 1×
“Drugs that relax chromatin by inhibiting histone deacetylase (HDAC) produce changes in hematopoietic differentiation similar to that produced by decitabine: terminal differentiation of leukemia cells (4, 16, 17), increased fetal hemoglobin expression (reviewed in ref.”
BackgroundHistone deacetylase activity is required for embryonic stem cell differentiation
Lee, J., Hart, S. R. L., & Skalnik, D. G. (2004) · genesis · doi:10.1002/gene.10250 · Cited by 280
Cited by
Tirino, V., Desiderio, V., Paino, F., De Rosa, A., Papaccio, F., La Noce, M., Laino, L., De Francesco, F., & Papaccio, G. (2013) · The FASEB Journal · doi:10.1096/fj.12-218222 · Cited by 395
“For instance, the demethylating agent 5-aza-2=-deoxycytidine has been shown to inhibit self-renewing population of CD34 cells (54).”
BackgroundReddington, J. P., Perricone, S. M., Nestor, C. E., Reichmann, J., Youngson, N. A., Suzuki, M., Reinhardt, D., Dunican, D. S., Prendergast, J. G., Mjoseng, H., et al. (2013) · Genome Biology · doi:10.1186/gb-2013-14-3-r25 · Cited by 240
“We generated Dnmt1 MEFs that stably expressed a short hairpin RNA against Dnmt1 (sh-Dnmt1 cells) [47].”
MethodKarahoca, M., & Momparler, R. L. (2013) · Clinical Epigenetics · doi:10.1186/1868-7083-5-3 · Cited by 213
“5-AZA-CdR also maintains hematopoietic precursor self-renewal [54].”
Molokie, R. E., Lavelle, D., Gowhari, M., Pacini, M., Krauz, L., Hassan, J., Ibañez, V., Ruiz, M. A., Ng, K. P., Woost, P. G., et al. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002382 · Cited by 156
Self-citationGu, X., Tohmé, R., Tomlinson, B. K., Sakre, N., Hasipek, M., Durkin, L. M., Schuerger, C., Grabowski, D., Zidan, A. M., Radivoyevitch, T., et al. (2020) · Leukemia · doi:10.1038/s41375-020-1003-x · Cited by 124
Self-citation
Metadata
- Authors
- Hu, Z., Negrotto, S., Gu, X., Mahfouz, R., Ng, K. P., Ebrahem, Q., Copelan, E., Singh, H., Maciejewski, J. P., & Saunthararajah, Y.
- Affiliations
- Cleveland Clinic (US)
- Corresponding author
- Saunthararajah, Yogen
- ORCID
- Venue
- Molecular Cancer Therapeutics
- Published
- 2010-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 1536-1543
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- PMC
- PMC2884053
- OpenAlex
- W2166833866
- Cited by
- 50
- References
- 33
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 3 · 2015: 5 · 2014: 3 · 2013: 6 · 2012: 8
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Americanae (AECID Library) (submittedVersion, cc-by-nc-sa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- U.S. Department of Defense
- Foundation for the National Institutes of Health
- Abraham J. and Phyllis Katz Foundation
- National Institutes of Health (1s10rr019391-01, 5r01hl082983-04)
- U.S. Food and Drug Administration
- National Heart, Lung, and Blood Institute (U54HL090513, R01-HL082983, K24HL077522)
- National Cancer Institute (R01CA138858)
- National Center for Research Resources (U54 RR 019391, S10-RR-019391)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- decitabine, hematopoietic stem cell self-renewal, DNMT1, DNA methylation, HOXB4, transcriptional repression, hematopoietic differentiation, PU.1, granulocyte colony-stimulating factor, cytosine analogues, hematopoietic precursors
- MeSH terms
- DNA (Cytosine-5-)-Methyltransferase 1, Decitabine, Proto-Oncogene Protein Spi-1, Animals, Azacitidine, Cell Differentiation, DNA (Cytosine-5-)-Methyltransferases, Hematopoietic Stem Cells, Humans, Proto-Oncogene Proteins, Repressor Proteins, Time Factors, Trans-Activators, Down-Regulation, Granulocyte Colony-Stimulating Factor, Homeodomain Proteins, Cell Lineage, RNA, Small Interfering, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus. https://app.cochat.ai/papers/10.1158/1535-7163.mct-10-0191
- The paper
- Hu, Z., Negrotto, S., Gu, X., Mahfouz, R., Ng, K. P., Ebrahem, Q., Copelan, E., Singh, H., Maciejewski, J. P., & Saunthararajah, Y. (2010). Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-10-0191
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.